Edgewise Q2 2026: $460.7M cash before Sevasemten close; $1.55B upfront received July 10; EDG-7500 Phase 3 on track for Q4
EWTX has more than doubled off its 52-week low of $12.3.
Summary
Edgewise reported Q2 2026 results with $460.7M in cash before the Sevasemten close. The $1.55B upfront from the Sevasemten Sale was received July 10, extending runway. EDG-7500 Phase 3 remains on track for Q4 2026.
Key Events · Earnings and Guidance · EWTX
-
Sevasemten Sale Closed July 10
Edgewise completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55B upfront, with up to $1.1B in potential milestones. The transaction closed on July 10, 2026, and the upfront cash was received.
-
Q2 2026 Financial Results
Net loss of $57.3M ($0.53/share) vs. $36.1M a year ago. R&D expenses rose to $47.5M from $33.6M, driven by EDG-7500 and EDG-15400 programs. Cash and marketable securities totaled $460.7M as of June 30, 2026.
-
Liquidity Runway Extended
With $460.7M on hand plus $1.55B from the Sevasemten Sale, management expects to fund operations for at least 12 months. The company also has a $175M ATM program available but has not used it.
-
EDG-7500 Phase 3 on Track for Q4 2026
Positive topline data from Part D of the Phase 2 CIRRUS-HCM trial was announced June 16, 2026. A Phase 3 trial in obstructive and nonobstructive HCM is targeted to initiate in Q4 2026.
Analysis · EWTX · Life Sciences
Edgewise's Q2 2026 10-Q offers the first view of its financial footing after the transformative $1.55B Sevasemten Sale, which closed on July 10, 2026. As of June 30, 2026, the company held $460.7M in cash and marketable securities, and with the $1.55B upfront proceeds, management expects this to fund operations for at least 12 months. The quarter's net loss widened to $57.3M from $36.1M a year ago, driven by increased R&D spending on EDG-7500 and EDG-15400. Positive topline data from Part D of the Phase 2 CIRRUS-HCM trial for EDG-7500 was announced in June, and a Phase 3 trial is targeted to initiate in Q4 2026. The filing also details the competitive landscape, including Cytokinetics' positive Phase 3 nHCM results and BMS's plans for a new Phase 3 nHCM trial. Now a pure-play cardiovascular biotech, the market will focus on execution of the EDG-7500 Phase 3 program and capital allocation from the Sevasemten proceeds.
At the time of this filing, EWTX was trading at $44.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $12.30 to $48.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.